EYEN Eyenovia Inc.

+0.15  (+3%)
Previous Close 5.3
Open 5.34
Price To Book 3.17
Market Cap 62506028
Shares 11,468,996
Volume 51,315
Short Ratio
Av. Daily Volume 319,932

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1H 2019.
Phase 3 trial not required - plan to proceed with registration activities 1H 2019.
Dry eye disease
Phase 3 trial met primary endpoint - January 31, 2019. Data from second trial also met primary endpoint - February 25, 2019. Detailed data due at (ASCRS) meeting May 3-7, 2019.
Mydriasis - pupil dilation
Phase 3 trial to be initiated 1H 2019.
Chronic angle closure glaucoma (CACG)

Latest News

  1. Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results
  2. Eyenovia to Participate in Two Upcoming Investor Conferences
  3. Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis
  4. Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering
  5. Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
  6. Biotech Stocks to Watch
  7. Biotechs Investors Are Flocking To
  8. 4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19)
  9. Eyenovia shares rocket on positive results in trial of device used to cause dilation of the eye
  10. Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
  11. Do Institutions Own Eyenovia, Inc. (NASDAQ:EYEN) Shares?
  12. 4 Healthcare Stocks to Watch on Wednesday (12/19/18)
  13. Eyenovia Prices Public Offering of Common Stock
  14. Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
  15. Eyenovia Initiates Phase III Study for Mydriasis Candidate
  16. The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial
  17. Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study
  18. Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics — Emerging Consolidated Expectations, Analyst Ratings